Cargando…

Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) is an aggressive disease with poor outcomes. Despite the incorporation of tyrosine kinase inhibitors (TKIs) in the therapeutic strategies, patients who relapse after chemotherapy plus TKI have poor overall survival (OS) and les...

Descripción completa

Detalles Bibliográficos
Autores principales: Micheva, Ilina, Gerov, Vladimir, Dimitrova, Stela, Efraim, Merlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175171/
https://www.ncbi.nlm.nih.gov/pubmed/34136291
http://dx.doi.org/10.1155/2021/1717506
_version_ 1783703000735285248
author Micheva, Ilina
Gerov, Vladimir
Dimitrova, Stela
Efraim, Merlin
author_facet Micheva, Ilina
Gerov, Vladimir
Dimitrova, Stela
Efraim, Merlin
author_sort Micheva, Ilina
collection PubMed
description Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) is an aggressive disease with poor outcomes. Despite the incorporation of tyrosine kinase inhibitors (TKIs) in the therapeutic strategies, patients who relapse after chemotherapy plus TKI have poor overall survival (OS) and less chance to proceed to hematopoietic stem cell transplantation (HSCT) which remains the only curative approach. Therefore, new drugs, such as antibody-targeted therapies alone or in combination with TKIs, offer new therapeutic options for those patients. However, the combination of inotuzumab plus ponatinib has limited application. We present a case of a patient affected by Ph + ALL with T315I mutation successfully treated after early relapse with inotuzumab plus ponatinib, followed by allogeneic HSCT and ponatinib maintenance.
format Online
Article
Text
id pubmed-8175171
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-81751712021-06-15 Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Micheva, Ilina Gerov, Vladimir Dimitrova, Stela Efraim, Merlin Case Rep Hematol Case Report Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) is an aggressive disease with poor outcomes. Despite the incorporation of tyrosine kinase inhibitors (TKIs) in the therapeutic strategies, patients who relapse after chemotherapy plus TKI have poor overall survival (OS) and less chance to proceed to hematopoietic stem cell transplantation (HSCT) which remains the only curative approach. Therefore, new drugs, such as antibody-targeted therapies alone or in combination with TKIs, offer new therapeutic options for those patients. However, the combination of inotuzumab plus ponatinib has limited application. We present a case of a patient affected by Ph + ALL with T315I mutation successfully treated after early relapse with inotuzumab plus ponatinib, followed by allogeneic HSCT and ponatinib maintenance. Hindawi 2021-05-26 /pmc/articles/PMC8175171/ /pubmed/34136291 http://dx.doi.org/10.1155/2021/1717506 Text en Copyright © 2021 Ilina Micheva et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Micheva, Ilina
Gerov, Vladimir
Dimitrova, Stela
Efraim, Merlin
Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
title Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
title_full Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
title_fullStr Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
title_full_unstemmed Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
title_short Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
title_sort efficacy of inotuzumab ozogamicin plus ponatinib followed by allogeneic stem cell transplantation in a patient with relapsed philadelphia chromosome-positive acute lymphoblastic leukemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175171/
https://www.ncbi.nlm.nih.gov/pubmed/34136291
http://dx.doi.org/10.1155/2021/1717506
work_keys_str_mv AT michevailina efficacyofinotuzumabozogamicinplusponatinibfollowedbyallogeneicstemcelltransplantationinapatientwithrelapsedphiladelphiachromosomepositiveacutelymphoblasticleukemia
AT gerovvladimir efficacyofinotuzumabozogamicinplusponatinibfollowedbyallogeneicstemcelltransplantationinapatientwithrelapsedphiladelphiachromosomepositiveacutelymphoblasticleukemia
AT dimitrovastela efficacyofinotuzumabozogamicinplusponatinibfollowedbyallogeneicstemcelltransplantationinapatientwithrelapsedphiladelphiachromosomepositiveacutelymphoblasticleukemia
AT efraimmerlin efficacyofinotuzumabozogamicinplusponatinibfollowedbyallogeneicstemcelltransplantationinapatientwithrelapsedphiladelphiachromosomepositiveacutelymphoblasticleukemia